Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.
AbbVie seeks to block imports of Alvotech’s biosimilar Humira into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.
Moderna has failed to reverse an unfavourable ruling related to its COVID-19 vaccine technology, after the US Court of Appeals for the Federal Circuit upheld the validity of a patent owned by Arbutus Biopharma.
Medical and human rights groups have called on US President Joe Biden to step up his personal engagement and help put in place a temporary waiver of IP rights for COVID-19 vaccines.
The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.
Medical device company SurgiSil has persuaded the US Court of Appeals for the Federal Circuit that its application for a design patent covering a lip filler was erroneously rejected by the US Patent and Trademark Office.
Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.